Belite Bio (BLTE) Non-Current Assets (2021 - 2026)
Belite Bio (BLTE) posted quarterly Non-Current Assets of $289.4 million for Q1 2026, up 5789.44% year-over-year from $4.9 million in Q1 2025, and up 1.09% quarter-over-quarter from $286.3 million in Q4 2025.
Belite Bio (BLTE) Non-Current Assets (2021 - 2026) Analysis & Trends
Belite Bio's Non-Current Assets history runs 6 years deep, the most recent figure standing at $289.4 million for Q1 2026.
- In Q1 2026, Non-Current Assets rose 5789.44% year-over-year to $289.4 million; the TTM figure through Mar 2026 stood at $304.9 million (up 1529.12% YoY), while the FY2025 annual figure was $286.3 million, up 5558.9% from the prior year.
- Non-Current Assets for Q1 2026 stood at $289.4 million, up from $286.3 million in the prior quarter.
- The five-year high for Non-Current Assets was $289.4 million in Q1 2026, with the low at $1.4 million in Q1 2023.
- The 5-year median for Non-Current Assets is $4.7 million (2023), against an average of $44.3 million.
- The sharpest annual moves came in 2025 and 2026: Non-Current Assets gained 5.02% in 2025, then surged 5789.44% in 2026.
- Belite Bio's Non-Current Assets stood at $1.5 million in 2022, then soared by 220.74% to $4.7 million in 2023, then climbed by 7.59% to $5.1 million in 2024, then jumped by 5558.9% to $286.3 million in 2025, then gained by 1.09% to $289.4 million in 2026.
- Business Quant data shows BLTE's Non-Current Assets at $289.4 million in Q1 2026, $286.3 million in Q4 2025, and $5.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Belite Bio | 6.40 Bn | 6.40 Bn | - | 289.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 289.41 Mn |
| Dec 31, 2025 | 286.28 Mn |
| Sep 30, 2025 | 5.18 Mn |
| Jun 30, 2025 | 5.44 Mn |
| Mar 31, 2025 | 4.91 Mn |
| Dec 31, 2024 | 5.06 Mn |
| Sep 30, 2024 | 4.55 Mn |
| Jun 30, 2024 | 4.57 Mn |
| Mar 31, 2024 | 4.68 Mn |
| Dec 31, 2023 | 4.70 Mn |
| Sep 30, 2023 | 1.46 Mn |
| Jun 30, 2023 | 1.56 Mn |
| Mar 31, 2023 | 1.40 Mn |
| Dec 31, 2022 | 1.47 Mn |
| Dec 31, 2021 | 917,000.00 |